EGENESIS, INC.

Profile

Company Names

EGENESIS, INC.

Addresses

101 CAMBRIDGEPARK DR., SUITE 200, CAMBRIDGE, MA 02140

300 TECHNOLOGY SQUARE, SUITE 301, CAMBRIDGE, MA 02139

C/O CAMBRIDGE BIOLABS, 1 KENDALL SQUARE, BUILDING 200, 2ND FLOOR, SUITE 2203, CAMBRIDGE, MA 02139

1071 BEACON STREET, UNIT 2, BROOKLINE, MA 02446

Phone Numbers

617-939-3643

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

2015

State Incorporated:

DELAWARE

Total Amount Raised:

$265,038,349.00

Number of Funding Rounds:

5
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
5
2024-02-13 
$25,419,995.00 
$28,719,296.00 
$3,299,301.00 
Debt 
4
2021-02-26 
$124,999,955.00 
$124,999,955.00 
$0.00 
Equity 
3
2019-11-01 
$100,000,000.00 
$100,000,000.00 
$0.00 
Equity 
2
2017-03-13 
$12,618,399.00 
$38,189,826.00 
$25,571,427.00 
Equity 
1
2016-08-08 
$2,000,000.00 
$3,000,000.00 
$1,000,000.00 
 
People
First Name
Middle Name
Last Name
Titles
Related Companies
JENNIFER 
 
BERGHEISER 
EXECUTIVE OFFICER
GEORGE 
M. 
CHURCH 
DIRECTOR
MICHAEL 
 
CURTIS 
EXECUTIVE OFFICER, DIRECTOR
KATHLEEN 
 
FANNING 
DIRECTOR
STEPHEN 
 
GILLIS 
DIRECTOR
PETER 
 
HANSON 
EXECUTIVE OFFICER
ARIEL 
 
JASIE 
EXECUTIVE OFFICER
RAHUL 
 
KAKKAR 
DIRECTOR
MARK 
 
PRUZANSKI 
DIRECTOR
SARAH 
 
SCHLESINGER 
DIRECTOR
SAPNA 
 
SRIVASTAVA 
EXECUTIVE OFFICER
ALBERT 
 
WIEGMAN 
DIRECTOR
ALBERT 
L. 
WIEGMAN 
DIRECTOR
LUHAN 
 
YANG 
EXECUTIVE OFFICER, DIRECTOR, PROMOTER
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
D
BIOTECHNOLOGY 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
DECLINE TO DISCLOSE 
Debt 
2024-02-13 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2021-02-26 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2019-11-01 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2017-03-13 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
 
2016-08-08 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#